Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diroximel fumarate - Alkermes/Biogen

Drug Profile

Diroximel fumarate - Alkermes/Biogen

Alternative Names: ALKS-8700; BIIB-098; VUMERITY

Latest Information Update: 22 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes plc
  • Developer Alkermes plc; Biogen
  • Class Anti-inflammatories; Fumarates; Pyrrolidines; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 11 Oct 2023 Updated efficacy data from a phase III EVOLVE-1 trial in Multiple sclerosis presented at 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis, 2023 (Joint ECTRIMS-ACTRIMS 2023)
  • 22 Apr 2023 Updated adverse events data from a phase III EVOLVE-1 trial in Multiple sclerosis presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)
  • 22 Apr 2023 Updated efficacy and adverse events data from a phase III EVOLVE-1 trial in Multiple sclerosis presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top